[Role of pelvic ultrasonography in the diagnosis, therapeutic indications and surveillance of central precocious puberty].
The use of pelvic ultrasonography was evaluated as a diagnostic and follow-up tool in girls with precocious puberty. Before treatment 23 of 33 patients with central precocious puberty presented an increased size of the uterus. In 10 cases with prepubertal size of the uterus, the precocious puberty was only beginning or of mild severity. During treatment with a LHRH analogue, changes in uterine size were slow in spite of a satisfactory and rapid control of estrogen secretion. At onset of treatment, transient ovarian cysts were seen in 2 patients. In our experience, pelvic ultrasonography did not provide significant information on the control of the disease by LHRH analogue therapy. Of 16 girls with presumed premature thelarche, 3 presented signs of estrogenic stimulation of the uterus. It remains a useful technique to rule out the presence of ovarian cysts or tumors at time of diagnosis.
D002064:Buserelin / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D010048:Ovarian Cysts / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000175:diagnosis; D010388:Pelvis; D011629:Puberty, Precocious / Q000175:diagnosis* / Q000503:physiopathology / Q000628:therapy; D014463:Ultrasonography
D002064:Buserelin
Place de l'échographie pelvienne dans le diagnostic, les indications thérapeutiques et la surveillance des pubertés précoces centrales.